Melanoma DNA vaccine - Vical

Drug Profile

Melanoma DNA vaccine - Vical

Latest Information Update: 08 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); Vical
  • Developer Vical
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 31 Oct 2001 Discontinued - Phase-II for Malignant melanoma in USA (Parenteral)
  • 18 Aug 1998 Phase-II clinical trials for Malignant melanoma in USA (Parenteral)
  • 05 Aug 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top